Injection in eye for wet AMD

The evidence base for intravitreal ranibizumab in diabetic macular edema is real but narrow: one 2019 cohort of 73 patients, all with diabetes, all treated, no untreated comparison group, and no long-term follow-up beyond the treatment course.

The study reports meaningful functional and structural gains. Best-corrected visual acuity improved from a mean LogMAR of 0.92 (roughly 20/160) to 0.61 (about 20/80), a statistically significant change with p<0.001 [1]. Central subfield thickness dropped from 425.2 to 328.6 micrometers, also p<0.001 [1]. Younger patients and those with worse baseline vision gained the most, and baseline retinal thickness strongly predicted final anatomical improvement [1]. Those are the numbers that exist.

Now the gaps. This is a single-center cohort, not a randomized trial. There is no control arm of untreated eyes, so you cannot separate the drug's effect from the natural history of diabetic macular edema, which sometimes improves on its own. The mean of 9.24 injections per eye over the study period tells you this is a maintenance therapy, not a cure [1]. The study does not report serious adverse events like endophthalmitis, retinal detachment, or thromboembolic events, which are the known risks of repeated intravitreal injection. Absence of reported harms in a 73-patient cohort is not evidence of safety; it is evidence that the study was too small to detect rare events.

The bigger problem is the question you asked. You asked about wet AMD. This study is about diabetic macular edema. The two are different diseases with different biology, different injection schedules, and different risk profiles. Ranibizumab is approved for both, but the evidence for wet AMD rests on the ANCHOR and MARINA trials from the mid-2000s, which are not in the retrieved records. I cannot cite what was not retrieved.

What I can say plainly: for wet AMD specifically, the retrieved evidence is empty. The one study here shows ranibizumab can improve diabetic macular edema in the short term, but it says nothing about wet AMD, nothing about long-term safety, and nothing about what happens after the injections stop. If you are weighing this treatment for wet AMD, the honest answer is that the evidence retrieved for this question does not cover it. The evidence for wet AMD exists in the broader literature, but it is not in front of me, and I will not pretend otherwise.

Confidence: high that the retrieved study shows short-term benefit in diabetic macular edema; zero confidence that it answers anything about wet AMD.